GE HealthCare Technologies Inc. (GEHC) Stock: Q4 Revenue Climbs 7% as Diagnostics and Imaging Lead 2025 Growth

TLDR

• GE HealthCare beats Q4 expectations as imaging and diagnostics surge
• Revenue climbs on strong global demand for advanced medical systems
• Pharmaceutical diagnostics jump over 22% in standout quarter
• Cash flow strength and acquisitions fuel 2026 expansion strategy
• Solid backlog and software growth position firm for steady gains

GE HealthCare Technologies closed at $78.78, down 1.66%, as the stock saw mild late-session pressure after earlier gains. Yet the company posted stronger fourth-quarter results that highlighted steady momentum across key product lines. Moreover, the update reinforced rising demand for diagnostics and imaging solutions through 2025.

GE HealthCare Technologies Inc., GEHC

Q4 Performance Strengthens Core Operations

GE HealthCare reported $5.7 billion in fourth-quarter revenue, and the figure rose 7.1% as pharmaceutical diagnostics, imaging, and advanced visualization supported growth. Organic revenue increased further as U.S. and EMEA markets drove higher volume. Total orders expanded 2.0% organically and lifted the book-to-bill ratio to 1.06.

Net income reached $589 million, and margin stood at 10.3% after tariff costs and mix shifts affected results. Adjusted EBIT totaled $950 million, and margin came in at 16.7% following continued operational investments.  Diluted EPS printed $1.29, while adjusted EPS reached $1.44 under tariff impacts.

Imaging delivered $2.55 billion in revenue and grew 6.6% as new systems supported clinical demand. Advanced Visualization Solutions posted $1.53 billion in revenue with a 5.9% increase driven by strong software utilization. Additionally, Pharmaceutical Diagnostics jumped 22.3% as expanded product output met global demand.

Full-Year Growth Supported by Diagnostics and Imaging Expansion

The company generated $20.6 billion in 2025 revenue and grew 4.8% as strong product adoption lifted annual output. Organic orders increased 5.2%, and the book-to-bill ratio reached 1.07, which confirmed healthy demand patterns across regions. Performance exceeded internal expectations due to consistent strength in Imaging, PDx, and AVS.

Net income registered $2.1 billion, and margin held at 10.1%, which showed resilience despite tariff exposure. Adjusted EBIT remained $3.2 billion, and margin reached 15.3%, supported partly by improved pricing and volume. Furthermore, diluted EPS climbed to $4.55 as cash generation held firm during the year.

Operating cash flow reached $2.0 billion, and free cash flow totaled $1.5 billion, supported by steady conversion rates. The company increased capital spending to $482 million as it expanded capacity and advanced its product roadmap. GE HealthCare executed share repurchases and maintained its quarterly dividend program.

Strategic Actions Position 2026 for Continued Expansion

GE HealthCare expanded its portfolio through acquisitions, including Nihon Medi-Physics and icometrix, which strengthened diagnostic capabilities. The company also announced plans to acquire Intelerad for $2.3 billion, and the deal aims to enhance cloud-enabled enterprise imaging. GE HealthCare expects the transaction to close in the first half of 2026 pending approvals.

The balance sheet ended the year with $4.5 billion in cash and $10.0 billion in total debt, which supported liquidity flexibility. Access to $3.5 billion in revolving credit enhanced the company’s ability to fund innovation and scale programs. Leadership outlined 2026 guidance that indicates growth across revenue, earnings, and cash flow.

Overall momentum improved as GE HealthCare advanced its precision-care strategy, and the company strengthened operations for broader global demand. The expansion across diagnostics, imaging, and software positioned the firm for sustained performance. GE HealthCare enters 2026 with solid backlog, strong cash flow, and a more diverse product engine.

The post GE HealthCare Technologies Inc. (GEHC) Stock: Q4 Revenue Climbs 7% as Diagnostics and Imaging Lead 2025 Growth appeared first on CoinCentral.